Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 11, 2005. The report details corporate governance activities, specifically changes in directors' share interests and a share buyback transaction executed under shareholder authority granted at the May 17, 2004 Annual General Meeting.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on equity transactions and share counts.
- Treasury Shares Held: 70,348,000 (post-transaction)
- Shares in Issue: 5,938,178,581 (excluding Treasury shares)
- Share Buyback Price: 1,236.2313 pence per share
- ShareReward Plan Price: 12.28 pounds per share
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback and the adjustment of director shareholdings via employee plans.
- Share Repurchase: The Company purchased 400,000 Ordinary shares on February 11, 2005, to be held in Treasury.
- Director Share Acquisitions: Mr. J D Coombe acquired 20 Ordinary shares (10 personal, 10 company-matched) under the ShareReward Plan on February 9, 2005.
- Trust Transfers: The GSK Trust transferred 48,860 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on February 10, 2005.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business performance, or discussion of risks and contingencies. It is a statutory disclosure of specific equity movements.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,938,178,581) against the latest capitalization table.
- Confirm the total Treasury share count (70,348,000) to assess potential dilution or future buyback capacity.
- Review the terms of the ShareReward Plan to understand the matching contribution mechanics utilized by Mr. Coombe.
- Check the remaining authority for share buybacks under the mandate granted on May 17, 2004.